Quinols as novel therapeutic agents. 2.1 4-(1-arylsulfonylindol- 2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents

Journal of Medicinal Chemistry

Volumn 48, Issue 2, 2005, Pages 639-644

  Berry, Jane M ^a   Bradshaw, Tracey D ^a   Fichtner, Iduna ^b   Ren, Ruobo ^c   Schwalbe, Carl H ^c   Wells, Geoffrey ^a   Chew, Eng Hui ^a   Stevens, Malcolm F G ^a   Westwell, Andrew D ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b M D Ctr Molec Med Berlin Buch   (Germany)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 ARYLSULFONYLINDOL 2 YL) 4 HYDROXYCYCLOHEXA 2,5 DIEN 1 ONE; 4 (1 BENZENESULFONYL 6 FLUORO 1H INDOL 2 YL) 4 HYDROXYCYCLOHEXA 2,5 DIENONE; 4,4 DIMETHOXYCYCLOHEXA 2,5 DIENONE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

AB INITIO CALCULATION; ACIDIFICATION; ADDITION REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEPROTECTION REACTION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MOUSE; NONHUMAN; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; CYCLOHEXANES; CYCLOHEXANONES; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYDROQUINONES; INDOLES; MICE; MICE, NUDE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; TRANSPLANTATION, HETEROLOGOUS;

EID: 12344254823     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040859h     Document Type: Article

References (15)

1. Part 1 of the series: Wells, G.; Berry, J. M.; Bradshaw, T. D.; Burger, A. M.; Seaton, A.; Wang, B.; Westwell, A. D.; Stevens, M. F. G. 4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines. J. Med. Chem. 2003, 46, 532-541.
2. Faaland, C. A.; Mermelstein, F. H.; Hayastin, J.; Laskin, J. D.; Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF) stimulated EGF receptor tyrosine kinase activity. Mol. Cell Biol. 1991, 11, 2697-2703.
3. Reddy, K. B.; Mangold, G. L.; Tandon, A. K.; Yoneda, T.; Mundy, G. R.; Zilberstein, A. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 1882, 52, 3631-3641.
4. Wells, G.; Seaton, A.; Stevens, M. F. G. Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein kinase inhibitors with hypervalent iodine reagents. J. Med. Chem. 2000, 43, 1550-1562.
5. Wells, G.; Bradshaw, T. D.; Diana, P.; Seaton, A.; Westwell, A. D.; Stevens, M. F. G. Antitumor benzothiazoles. 10. The synthesis and antitumor activity of benzothiazole substituted quinol derivatives. Bioorg. Med. Chem. Lett. 2000, 10, 513-515.
6. Ibaceta-Lizana, J. S. L.; Jackson, A. H.; Prasitpan, N.; Shannon, P. V. R. Electrophilic substitution in indoles. Part 13. The synthesis and rearrangement of 2-deuteriospiro[cyclopentane-3′-indolenine]. J. Chem. Soc., Perkin Trans. 2 1987, (9), 1221-1226.
7. Nicolaou, I.; Zaher, D.; Vassilis, J. Synthesis of N-protected 1H-indole-5-carboxylic acids with aldose reductase inhibitory potential. Org. Prep. Proc. Int. 2002, 34, 501-504.
8. Nyasse, B.; Grehn, L.; Maia, H. L. S.; Monteiro, L. S.; Ragnarsson, U. 2-Naphthalenesulfonyl as a tosyl substitute for protection of amino functions. Cyclic voltammetry studies on model sulfonamides and their preparative cleavage by reduction. J. Org. Chem. 1999, 64, 7135-7139.
9. Capparelli, M. P.; DeSchepper, R. E.; Swenton, J. S. Structural and solvent/electrolyte effects on the selectivity and efficiency of the anodic oxidation of para-substituted aromatic ethers. J. Org. Chem. 1987, 52, 4953-4961.
10. Katritzky, A. R.; Aslan, D. C.; Leeming, P.; Steel, P. J. Asymmetric induction using chiral 1,2,4-triazole and benzimidazole derivatives. Tetrahedron Asymmetry 1997, 8, 1491-1500.
11. Katritzky, A. R.; Lue, P.; Chen, Y. X. An alternative route to 2-substituted indoles via N-aminal-directed lithiation. J. Org. Chem. 1990, 55, 3688-3691.
12. Schmidt, M. W.; Baldridge, K. K.; Boatz, J. A.; Jensen, J. H.; Koseki, S.; Gordon, M. S.; Nguyen, K. A.; Windus, T. L.; Elbert, S. T. General atomic and molecular electronic structure system. QCPE Bull. 1990, 10, 52-54.
13. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 34, 91-104.
14. Weinstein, J. N.; Myers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace, A. J.; Kohn, K. W.; Fojo, T.; Bates, S. E.; Rubinstein, L. V.; Anderson, N. L.; Buolamwini, J. K; van Osdol, W. W.; Monks, A. P.; Scudiero, D. A.; Sausville, E. A.; Zaharevitz, D. W.; Bunow, B.; Viswanadhan, V. N.; Johnson, G. S.; Wittes, R. E.; Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275, 343-349.
15. Kunkel, M. W.; Kirkpatrick, D. L.; Johnson, J. I.; Powis, G. Cell line-directed screening assay for inhibitors of thioredoxin reductase signalling as potential anti-cancer drugs. Anti-Cancer Drug Des. 1997, 12, 659-670.